Journals / Akdeniz Tıp Dergisi / 2017 / Cilt: 3 - Sayı: 3

Multiple Sclerosis

Multipl Skleroz

Pages
137–147
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this context, understanding the onset and progression of this disease and testing new treatment approaches for MS animal models play an important role

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Multiple sclerosis MS is a chronic autoimmune, demyelinating disease that affects the central nervous system, usually in young adults.
📊
Key Findings & Data:In Europe and the United States of America, the prevalence is 1 in a thousand young adults.
💡
Conclusion & Impact:In this context, understanding the onset and progression of this disease and testing new treatment approaches for MS animal models play an important role
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Multipl Skleroz · Demiyelinizasyon · Remiyelinizasyon

Abstract

Multiple sclerosis MS is a chronic autoimmune, demyelinating disease that affects the central nervous system, usually in young adults. Mostly the myelin sheaths and oligodendrocytes, and to a smaller extent the axons and neuron cells are damaged in MS. In Europe and the United States of America, the prevalence is 1 in a thousand young adults. In Turkey, epidemiological studies have shown that the MS prevalence is 0.4-1 per thousand. In the early 20th century, MS became one of the most common neurological disorders. Nowadays 2.5 million people have MS. Treatment and maintenance of these patients costs billions of dollars. Even though genetics and environmental factors are thought to play an important role in MS pathophysiology, an MS-specific pathogenesis is not yet described. In this context, understanding the onset and progression of this disease and testing new treatment approaches for MS animal models play an important role

Özet

MS , genelde genç erişkinlerde santral sinir sistemini etkileyen, kronik, otoimmün ve demiyelinizan bir hastalıktır. Miyelin kılıflar, oligodendrositler ve daha az oranda aksonların ve nöronların hasarlandığı bir hastalıktır. Avrupa ve Amerika Birleşik Devletleri’nde görülme sıklığı, her 1000 genç yetişkinde 1’dir. Türkiye’de ise gerçekleştirilen epidemiyolojik çalışmalarda, MS prevelansı 1000 genç yetişkinde 0,4-1 arasında izlenmiştir. MS 20. yüzyılın başlarında nörolojide en sık görülen hastalıklardan biri haline gelmiştir. Günümüzde dünyada 2,5 milyon MS hastası vardır. Bu hastaların tedavisi ve bakımı milyarlarca dolara mal olmaktadır. Bugüne kadar MS patofizyolojisinde genetik ve çevresel risk faktörlerinin önemli rol oynadığı düşünülmesine rağmen MS için spesifik bir patogenez tanımlanmamıştır. Bu bağlamda MS hayvan modelleri hastalığın başlangıcı ve progresyonunun anlaşılmasında ve hastalık için yeni tedavi yaklaşımlarının test edilmesinde önemli rol oynamaktadır

🔖

Cite This Article

ÖZTÜRK, S., KIZILAY, F., AYTAÇ, G., SİNDEL, M. (2022). Multiple Sclerosis. Akdeniz Tıp Dergisi, Cilt: 3 - Sayı: 3, 137–147. https://ajindex.com/articles/434471

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Hafler DA, Slavik JM, Anderson DE, O’Connor KC, De Jager P, Baecher-Allan C. Multiple sclerosis. Immunological Reviews 2005;204:208-31.
  2. Compston A, Confavreux C, Lassman H, McDonald I, Miller D, Noseworthy J. The story of multiple sclerosis. McAlpine’s Multiple Sclerosis. Philadelphia: Churchill Livingstone Elsevier, 2006:3. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. New England Journal of Medicine 2000;343:938-52.
  3. Compston A, Coles A. Multiple sclerosis. Lancet 2002;359:1221-31.
  4. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Annals of Neurology 2000;47:707-17.
  5. Sospedra M, Martin R. Immunology of multiple sclerosis. Annual Review of Immunology 2005;23:683-747.
  6. Pasquini MC, Griffith LM, Arnold DL, Atkins HL, Bowen JD, Chen JT, Freedman MS, Kraft GH, Mancardi GL, Martin R, Muraro PA, Nash RA, Racke MK, Storek J, Saccardi R. Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies. Biology of blood and marrow transplantation. Journal of the American Society for Blood and Marrow Transplantation 2010;16:1076-83.
  7. Turk Boru U, Alp R, Sur H, Gul L. Prevalence of multiple sclerosis door-to-door survey in Maltepe, Istanbul, Turkey. Neuroepidemiology 2006;27:17-21.
  8. Bulut S, Kılıç H, Demir C. Yukarı Fırat Bölgesinde multipl skleroz tanısı ile izlenen hastaların klinik ve demografik özellikleri. Fırat Tıp Dergisi 2011;16:84-90. Paradiso S. Neuroimaging: A companion to Adams and Victor’s principles of neurology - Greenberg, JO. Am J Psychiat 1996;153:729-729.
  9. Nielsen NM, Westergaard T, Rostgaard K, Frisch M, Hjalgrim H, Wohlfahrt J, Koch-Henriksen N, Melbye M. Familial risk of multiple sclerosis: A nationwide cohort study. American Journal of Epidemiology 2005;162:774- 8. Rosati G. The prevalence of multiple sclerosis in the world: An update. Neurol Sci 2001;22:117-39.
  10. Sheikh A, Strachan DP. The hygiene theory: Fact or fiction? Current Opinion in Otolaryngology & Head and Neck Surgery 2004;12:232-6. Hayes CE. Vitamin D: A natural inhibitor of multiple sclerosis. Proceedings of the Nutrition Society 2000;59:531-5. Karabudak R. Klinik nöroimmünolojiye giriş. In: Karabudak R. ed, Temel ve Klinik Nöroimmünoloji. Ankara: ADA Basın Yayın Ltd. Şti., 2013:177. Frohman EM, Racke MK, Raine CS. Multiple sclerosis- the plaque and its pa